Phenserine on the Alzheimer's Treatment Horizon, Study 1

Inclusion Criteria: * A diagnosis of AD based on the most recent NIA-AA diagnostic criteria for AD. * A significant change on a validated AD amyloid or tau biomarker (as determined either by visual reading of amyloid PET scans \[using any of the approved ligands\], or CSF Aβ 1-42 or blood p-tau 217 levels \[cut-off as determined by the individual laboratory. * A CDR Global rating of 0.5 or 1.0. * An MRI scan within the past two years that has no findings inconsistent with AD. * Participants who have recently participated in other clinical trials or have been under treatment with memantine or acetylcholinesterase inhibitors (e.g., Donepezil, Rivastigmine, Galantamine) must undergo a washout period of at least 4 weeks prior to the start of the study. * Capacity to give informed consent based on the clinical judgement of an experienced clinician. * The participant has an individual who is in regular, daily contact via phone or in-person visits and who can act as a reliable study partner and provide meaningful input into rating scales. * Age ≥50 years. * Fluency in Norwegian and evidence of adequate premorbid intellectual functioning. * Capable of participating in all scheduled evaluations and complete all required tests. * Female participants must be of non-childbearing potential or have a negative serum pregnancy test up to 24 hours prior to the baseline assessments and agree to use effective birth control throughout their participation in the study from signing informed conse…